feed,title,long_url,short_url
Benzinga,FDA Approves G1 Therapeutics' COSELAâ„¢ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression,https://www.benzinga.com/pressreleases/21/02/g19652875/fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decr,https://j.mp/3adzoXM
